- Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) enters into an exclusive global licensing deal with privately-held Immunomic Therapeutics for its LAMP-vax technology in allergic diseases. Under the terms of the agreement, Immunomic will receive an upfront payment of $300M plus 10% royalties on net sales. Astellas has worldwide rights to research, develop, manufacture and commercialize any LAMP-vax products for the treatment of allergic diseases in humans, including ARA-LAMP-vax for peanut allergy.
- Immunomic retains the rights to LAMP-vax for other applications, including cancer immunotherapy.
-
LAMP (Lysosomal Associated Membrane Protein)-vax is a next-generation DNA vaccine that stimulates an immune response against a particular protein by injecting the DNA encoding the protein rather than the protein itself. It initiates a more complete immune response, including antibody production, cytokine release and critical immunological memory.